1 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition. International Agency for Research on Cancer, World Health Organization 2017.
2 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
3 Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol. 2001;144:682–95.
4 Dodd NJ, Bond MG. Fatal anaphylaxis in systemic mastocytosis. J Clin Pathol. 1979;32:31–4.
5 King JJ, Crawford EA, Iwenofu OH, Fox EJ. Case report: pathologic long fracture in a patient with systemic mastocytosis. Clin Orthop Relat Res. 2007;459:263–9.
6 Sagher F, Even-Paz Z. Incidence of mastocytosis. In: Mastocytosis and the mast cell. Herausgeber: Sagher F, Even-Paz Z. Basel, New York: Karger, pp. 14–17, 1967.
7 Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737–46.
8 Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374:2530–41.
9 Reinhart S, Rüfer A, Zimmermann D, Dommann-Scherrer C, Lerch M, Goede JS. Wenn Mastzellen krank machen. Swiss Med Forum. 2019;19(31–32):507–11.